Drugs / Sodium Fluorescein
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02677623 | Mar 2015 → Aug 2016 | — | Columbia University | Completed | No outcome recorded |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT03752203 | Aug 2021 → Jun 2023 | central nervous system neoplasm | University of Colorado, Denver | Terminated | No outcome recorded |
| — | NCT02971800 | Aug 2016 → Jan 2017 | — | CHU de Quebec-Universite Laval | Completed | No outcome recorded |
| — | NCT02476448 | Feb 2015 → Feb 2016 | ureteral disorder | Cecilia Calvo | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT02757417 Comparator | Jul 2016 → Jan 2018 | — | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Fluorescein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03752203 ↗ |
| Known as | Fluorescein sodium | “Fluorescein sodium is a small organic salt that accumulates in areas of diminished blood-brain barrier integrity and allows for determination of the margins between tumor and...” NCT03752203 ↗ |
| Modality | Diagnostic / imaging agent | “intravenous sodium fluorescein to visualize ureteral efflux during intraoperative cystoscopy” NCT02971800 ↗ |
| Route | Intravenous | “Administered intravenously and assessed during cystoscopy” NCT02476448 ↗ |